EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 2 
   2. SUMMARY OF CHANGES 
Not appli
cable. 

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 4 
   4. SYNOPSIS 
Name [CONTACT_790]/Company : Endo Pharmaceuticals Inc . 
Name [CONTACT_791] : EN3835  
Name [CONTACT_3261] : Collagenase clostridium histolyticum  
Title of Study : A Phase 2 Open -label Study of EN3835 in the Treatment of Edematous Fibrosclerotic 
Panniculopathy  
Lead Principal Investigator : [INVESTIGATOR_903760] :  
Estimat ed date first subject  enrolled:  Nov-[ADDRESS_1267622] completed:  Jul-2018  Phase of Development : 2 
Objectives : 
Primary Objective : 
 To assess the safety of EN3835 in the treatment of edematous fibrosclerotic panniculopathy 
(EFP), commonly known as cellulite, in adult women  
Secondary Objective : 
 To assess effectiveness of EN3835 in the treatment of EFP  
Study Design : This study is a Phase 2, open -label study of safety and effectiveness of EN3835 in the 
treatment of EFP in adult women. Subjects will be screened for study eligibility within [ADDRESS_1267623] 2 bilateral treatment areas (bilateral buttocks or bilateral 
posterolateral thighs) (a lso referred to as a region) (eg , their left and right buttocks or left and righ t 
posterolateral thighs) with mild, moderate or severe levels of cellulite as assessed by [CONTACT_903764] (CR -PCSS) and a Hexsel Cellulite 
Severity Scale no greater than 13 will be eligibl e. If both their left and right buttocks AND left and right 
posterolateral thighs are eligible, one pair will be randomly selected a s the assigned treatment areas.  
Subjects will receive an open -label treatment course which consists of up to 3 treatment vis its  
(ie, Day1, Day 22, and Day 43). Each treatment visit will consist of 12 injections (0.3 mL per injection 
of EN3835 0.07 mg/injection) in each of the treatment areas of the region for a total volume of 7.2 mL 
(1.68 mg). Selection of dimples to be treat ed in the assigned treatment areas will be at the discretion of 
the Investigator. End -of-study will occur at study Day 180.  
At each treatment visit, the Investigator  will first conduct a live assessment of each treatment area of the 
assigned region using the CR -PCSS. The Investigator  will then select and mark the dimples to be treated 
within each treatment area. All the assessments must be done before marking the dimp les for injection.  
At Day 180 (End of Study/Early Termination), The Investigator  will conduct live assessments of each of 
the treatment area using the CR -PCSS. The subject will complete the Subject Satisfaction with Cellulite 
Treatment assessment.  
In a pho tographic sub -study at two sites, subjects will return to the site to have their treated areas 
photographed at 1, 3, 6, and [ADDRESS_1267624]-injection.  
Number of Subjects (planned) : Up to 150  
Study Center(s) : Approximately 10 sites in [LOCATION_002]  

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 5 
   Name [CONTACT_790]/Company : Endo Pharmaceuticals Inc . 
Name [CONTACT_791] : EN3835  
Name [CONTACT_3261] : Collagenase clostridium histolyticum  
Diagnosis and Inclusion/ Exclusion Criteria : 
Inclusion Criteria : 
1. Voluntarily sign and date an informed consent agreement  
2. Be a female ≥[ADDRESS_1267625] one treatment region (bilateral buttocks or bilateral 
posterolateral thighs), with each region treatment area having:  
a. a score of 2 (mild) or greater as reported by [CONTACT_737] (CR -PCSS), and  
b. a Hexsel CSS score no greater than 13  
4. Be willing to apply sunscreen to the assig ned treatment areas before each exposure to the sun 
while participating in the study (ie , Screening through end of study)  
5. Be judged to be in good health, based upon the results of a medical history, physical 
examination, and laboratory profile at Screening  
6. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test before 
injection of study drug and be using a stable and ef fective contraception method (e g, abstinence, 
intrauterine device [IUD], hormonal [estrogen/progestin] contrac eptives, or double barrier 
method) for at least 1 menstrual cycle prior to study enrollment and for the duration of the 
study; or be menopausal defined as 12  months of amenorrhea in the absence of other biological 
or physiological causes, as determined by [CONTACT_737]; or post -menopausal for at least 
1 year; or be surgically sterile  
7. Be willing and able to cooperate with the requirements of the study  
8. Be able to read, complete and understand the patient -reported outcomes rating instruments in 
English  
Excl usion Criteria :  
A subject will be excluded from study participation if she:  
1. Has any of the following systemic conditions:  
a. Coagulation disorder  
b. Evidence or history of malignancy (other than excised basal -cell carcinoma) unless there 
has been no recurrence in at least [ADDRESS_1267626]’s well -being. Any 
questions about concurrent diseases should be discussed with the Medical Monitor.  
e. Evidence of clinically significant abnormalities on physical examination, vital signs, 
electrocardiogram (ECG), or clinical laboratory values  
2. Has any of the following local c onditions in the area to be treated:  
a. History of lower extremity thrombosis or post -thrombosis syndrome  
b. Vascular d isorder (eg , varicose veins, telangiectasia) in area to be treated  
c. Inflammation or active infection  
d. Active cutaneous alteration including rash,  eczema, psoriasis, or skin cancer  
e. Has a tattoo and/or a mole located within 2 cm of the site of injection  
3. Requires the following concomitant medications before or during participation in the trial:  
a. Anticoagulant or antiplatelet medication or has received  anticoagulant or antiplatelet 
medication (except for ≤150 mg aspi[INVESTIGATOR_34223]) within 7 days before injection of study drug  

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 6 
   Name [CONTACT_790]/Company : Endo Pharmaceuticals Inc . 
Name [CONTACT_791] : EN3835  
Name [CONTACT_3261] : Collagenase clostridium histolyticum  
4. Has used any of the following for the treatment of EFP on the legs or buttocks within the 
timelines identified below or intends to use any of the following at any time during the course of 
the study:  
a. Liposuction in the areas of the body selected for treatment during the 12 -month period 
before injection of study drug  
b. Injections (eg, mesotherapy); radiofrequency device treatments; laser  treatment; buttock 
and/or thigh implant treatment, cryolipolysis, or surgery (including subcision and/or 
powered subcision) within the assigned treatment areas during the 12 -month period before 
injection of study drug  
c. Endermologie or similar treatments wi thin the assigned treatment areas during the 6 -month 
period before injection of study drug  
d. Massage therapy within the assigned treatment areas during the 3 -month period before 
injection of study drug  
e. Creams (eg, Celluvera™, TriLastin®) to prevent or mitiga te EFP within the assigned 
treatment areas during the [ADDRESS_1267627] ridium histolyticum 
(CCH) : AUX -CC-830, AUX -CC-831, EN3 835-102, EN3835 -104, EN3835 -201, and/or 
EN3835 -202 
14. Any other condition(s) that, in the Investigator’s opi[INVESTIGATOR_1649], might indicate the subject to be 
unsuitable for the study  
Investigational Product, Dosage and Mode of Administration :  
EN3835, 1.68 mg, subcutaneous. A  dose of 0.84 mg of EN3835 per treatment area will be administered 
as 12 subcutaneous injections (0.3 -mL injection administered as three 0.1 -mL aliquots per injection) in 
each of two treatment areas  for a total dose of 1.68 mg and a total vo lume of 7.2 mL (3.6 mL per 
treatment area). Total number of injections will be 24 injections per treatment visit into the assigned 
region (left and right buttocks or left and right posterolateral thighs). There will be 3 treatment visits at 
21-day interval s, ie, treatments on Days 1, 22, and 43 will be administered.  
Duration of Study : Up to 194 days (includes screening phase)  
Screening Phase : Up to 14 days  

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 8 
   Name [CONTACT_790]/Company : Endo Pharmaceuticals Inc . 
Name [CONTACT_791] : EN3835  
Name [CONTACT_3261] : Collagenase clostridium histolyticum  
Immunogenicity: Anti -AUX -I and anti -AUX -II antibody levels will be summarized using descriptive 
statistics for the actual value at the visit. Samples from Day 1 and Day 180 will be analyzed for 
anti-AUX -I and anti -AUX -II and a subset will be analyzed for neutralizing antibodie s. 
Effectiveness Endpoints : 
 Proportion at each level of improvement in the CR -PCSS of each assigned treatment area 
(Days 22, 43, 90, and 180):  
 Proportion of responders defined as subjects with an improvement in severity from 
baseline of at least 2 le vels of severity in the CR -PCSS  
 Proportion of responders defined as subjects with an improvement in severity from 
baseline of at least 1 level of severity in the  CR-PCSS  
 Number of responses at each level of the subject satisfaction with cellulite treatment 
(Day  180)  
All effectiveness endpoints will be summarized as numbers and percentages.  
 

EN3835 -205 Protocol   
31-Aug-2017 Endo Pharmaceuticals Inc. Page 10 
   Procedures  Day -14 
to -1 
Screening  Day 1  
(Baseline)  Post-Injection Day  
Day 22  
(±3 d)  Post-Injection Day  
Day 43  
(± 3 d)  Post-Injection Day  
Day 90  
(± 7d)  Day 180  
(+ 7 d)  
EOS/  
ET  
1 3 6 13 1 3 6 13 1 3 6 13 Unsched . 
Visit  
 Injection site reactions/local 
tolerability in assigned treatment 
areas   X X X X X X X X X X X X X X X X X  
 Adverse events  Monitored Throughout Study  
a Before injection. 
b Up to 4 hours before injection; approximately [ADDRESS_1267628] be ≤[ADDRESS_1267629] on Screening and Day 180/EOS/ET, and any Unscheduled Visits; urine pregnancy test on Day 1, Day 22, Day 43, and Day 90 visits  
d=Days; ECG=Electrocardiogram; EFP=Edematous fibrosclerotic panniculopathy 
 

EN3835-[ADDRESS_1267630] OF ABBR
EVIATION
S .....................................................................................17
8. INTRODU
CTION 
................................................................ ......................................18
8.1. Background 
.................................................................................................................18
8.1.1. Edema
tous Fibroscleroti
c Panniculopathy .................................................................18
8.1.2. Current EFP Treat
ments
 .............................................................................................18
8.1.3. EN3835 (Co
llagenase Clostr
idium Histolyticum) ................................ ......................[ADDRESS_1267631] Sc
reening ................................
.......................................................................31
[IP_ADDRESS]. Medical His
tory 
................................................................
..........................................31
[IP_ADDRESS]. Screening Period (Day -14 to Day - 1) ........................................................................31
[IP_ADDRESS].
Assignment
 of Trea
tmen
t Areas .................................................................................32
12.2. Selecting an
d Marking Di
mples during Treatment ....................................................32
12.3. Treatm
ent Visit 1 
(Day 1) ...........................................................................................33
12.3.1. Treatm
ent Visit 1
: Pre-Injection .................................................................................33
12.3.2. Treatm
ent Visit 1
: Injection and Post-injection ..........................................................34
12.4. Follow
-up Visi
ts at 1, 3, 6, and 13 Days Following Each Treatment Visit ................34
12.4.1. For Sites Pa
rticipati
ng in the Photographic Sub-study (section 12.12) ......................34
12.4.2. For Sites no
t Participa
ting in the Photographic Sub-study ................................ .........34
12.5. Treatm
ent Visit 2 
(Day 22 [±3 days]) and Treatment Visit 3 (Day 43 [±3 
days]) ..........................................................................................................................34
12.5.1. Treatm
ent Visits 2 and 3:
 Pre-injection ......................................................................34
12.5.2. Treatm
ent Visits 2 and 3:
 Injection and Post-injection  ..............................................35
12.6. Day 90 (±3 days)
 ................................................................
........................................35
12.7. Day 180 (+7 days)
 End- of-Study /
 Earl y Termination ...............................................36
12.8. Unschedule
d Visits  .....................................................................................................36
12.9. Prior and Co
ncomitant
 Medications and Procedures ..................................................36
12.9.1. Prohibited 
Medications or Procedures 
........................................................................36
12.10. Treatm
ent Com
pliance ................................................................................................37
12.11. Blinding an
d Randomiz
ation ......................................................................................37
12.12. Photographic Sub
-study 
.............................................................................................. 37
12.13. Medical Sta
tus Follow- up 
...........................................................................................37
13. ASSES
SMENT OF E
FFECTIVENESS .....................................................................38
13.1. Effecti
veness Measurements
 ......................................................................................38
13.1.1. Clinic
ian-
Reported Photonumeric Cellulite Severity Scale (CR-PCSS) ....................[ADDRESS_1267632] Sa
tisfaction with Cellulit
e Treatment Assessment ........................................38
13.1.3. Hexsel Cellulite Severity S
cale 
................................................................ ..................39

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 13 
 14. ASSESSMENT O
F SAFETY .....................................................................................41
14.1. Defini
tions 
................................................................................................ ..................41
14.1.1. Adverse Events
 ................................................................
...........................................41
14.1.2. Serious Adv
erse Events 
..............................................................................................41
14.2. Monitoring 
Adverse Events ................................
................................ ........................42
14.3. Relation
ship to Study Drug 
........................................................................................42
14.4. Intensity As
sessment
 ..................................................................................................43
14.5. Reporting A
dverse Events and Serious Advers
e Events  ............................................43
14.5.1. Reporting A
dverse Events 
..........................................................................................43
14.5.2. Reporting S
erious Advers
e Events ................................................................ .............43
[IP_ADDRESS]. Follow
-up Procedures for Serious Ad
verse Events
 ....................................................[ADDRESS_1267633]  .............................................................................44
14.6.2. Overdose/M
isuse/Abuse
 ................................ .............................................................44
[IP_ADDRESS]. Overdose 
.....................................................................................................................44
14.6.3. Pregnancy
 ................................ ...................................................................................45
14.6.4. AEs/SAEs Experienced
 by [CONTACT_51584]-subjects Exposed to Study Medication ...................[ADDRESS_1267634] Pop
ulations 
................................................................ ....................................51
17.2.1. Safety Population 
................................................................................................ ........51
17.2.2. Effectiveness Population ............................................................................................51
17.2.3. Per-
Protocol (PP) Population
 ......................................................................................[ADDRESS_1267635] Dispositi
on ................................
.....................................................................51
17.4. Demographics and Other Baseline Characteristics .....................................................51

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 14 
   17.5. Effectiveness Analyses  ...............................................................................................52  
17.5.1. Effectiveness Variables  ..............................................................................................52  
17.6. Safety Analyses ..........................................................................................................52  
17.6.1. Prior, Concomitant, and Follow-up Medication .........................................................52  
17.6.2. Study Drug Exposur
e ..................................................................................................52  
17.6.3. Measurement of Treatment Compliance ....................................................................53  
17.6.4. Adverse
 Events ...........................................................................................................53  
17.6.5. Vital Signs ..................................................................................................................53  
17.6.6. Clini
cal Laboratory Parameters ..................................................................................54  
17.6.7. Elec
trocardiogram .......................................................................................................54  
17.6.8. Physic
al Examination .................................................................................................54  
17.6.9. Other
 Safety Measurements ........................................................................................54  
17.7. Pharm
acokinet ic Analyses ..........................................................................................54  
17.8. Pharmacodynam ic Analyses .......................................................................................54  
17.9. Other Data (eg, Heal th Economics/QOL, Pharmacogenetic, etc.) .............................[ADDRESS_1267636] ACC ESS TO SOURCE DATA/DOCUMENTS .........................................[ADDRESS_1267637] (IRB) ...............................................................................[ADDRESS_1267638] Con
fidentiali
ty ................................ ...............................................................65
25. TERMI
NATION OF STUD
Y ....................................................................................66
26. INVESTIG
ATOR’S ST
ATEMENT  ...........................................................................67
27. REFERENCES 
...........................................................................................................68
APPENDIX 
A. DOCUMENTS REQUIRED PRIOR TO INITIATION OF THE 
STUDY 
..............................................................................................................69
APPENDIX 
B.CLINICIAN-REPORTED PHOTONUMERIC CELLULITE 
SEVER
ITY SCALE (CR-PCSS) FOR THE BUTTOCK .................................71
APPENDIX 
C.CLINICIAN-REPORTED PHOTONUMERIC CELLULITE 
SEVER
ITY SCALE (CR-PCSS) FOR THE THIGH .......................................72
APPENDIX 
D. HEXSEL DM, DAL’FORNO T, HEXSEL CL. A VALIDATED 
PHOTONU
MERIC CELLULITE SEVERITY SCALE. J EUR ACAD 
DERMATOL VENEREOL . 2009;23(5):523-[ADDRESS_1267639] OF TABLES 
Table 1: Sponsor Conta
ct Information ........................................................................................3
Table 2: Abbrevi
ations and Special Terms ...............................................................................17
Table 3: Study Tre
atment Groups .............................................................................................24
Table 4: Conco
mitant Medication Restrictions for Subjects During the Treatment 
Phase of Study ............................................................................................................37
Table 5: Subjec
t Satisfaction with Cellulite Treatment Assessment - Buttocks .......................38
Table 6: Subjec
t Satisfaction with Cellulite Treatment Assessment - Thighs ..........................39
Table 7: Hexsel
 Cellulite Severity Scale ..................................................................................40
Table 8: Clini
cal Laboratory Tests ...........................................................................................46
Table 9: Vita
l Signs Measurements on Injection Day ..............................................................47
Table 10: Fit
zpatrick Scale .........................................................................................................[ADDRESS_1267640] OF FIGURES
 
Figure 1: Study Design ...............................................................................................................24
Figure 2:
Study Drug Administration at Each Injection Site .....................................................26
Figure 3:
Examples of Subject Dimple and Injection Site Markings .........................................[ADDRESS_1267641] OF ABBREVIATION S  
The foll
owing abbreviations and special terms are used in this study protocol. 
Table 2: Abbreviations and Special Terms 
Abbreviation  Definition  
AE Adverse event  
AUX -I Clostridial class I collagenase  
AUX -II Clostridial class II collagenase  
BMI  Body mass index  
CRF  Case report form  
CR-PCSS  Clinician -Reported Photonumeric Cellulite Severity Scale  
CSS Cellulite Severity Scale 
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EFP Edematous fibrosclerotic panniculopathy  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HREC  Human Research Ethics Committee  
IB Investigator brochure  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
I-GAIS  Investigator -Global Aesthetic Improvement Scale  
IRB Institutional Review Board  
IWRS  Interactive web response system  
LOCF  Last Observation Carried Forward  
PR-PCSS  Patient -Reported Photonumeric Cellulite Severity Scale  
Qualified designee  Qualified by [CONTACT_596635] 
(eg, sub-Investigator, nurse).  
Region  Bilateral buttocks or bilateral thighs (each cons isting of 2 treatment areas, ie , 
left/right buttock or left/right thigh). To be suitable for treatment, the region 
must have an Investigator CR -PCSS score of [ADDRESS_1267642] – Global Aesthetic Improvement Scale  
TEAE  Treatment -emergent adverse event. Adverse events that occur on or after the 
first injection of study drug.  
Treatment area  Left buttock, right buttock, left thigh, or right thigh.  
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 18 
   8. INTRODUCTION 
8.1. Back
ground 
8.1.1.  Edematous Fibrosclerotic Panniculopathy 
Edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite, has been defined 
as a local metabolic disorder of subcutaneous tissues that results in a contour abnormality of the 
skin.( 1) The condition manifests as dimpled skin, particularly in the gluteal-femoral region.( 2,3) 
EFP is caused by [CONTACT_596637]. 
This creates an uneven surface with dimpling.( 1) EFP is a medical condition resulting in a 
potentia
lly cosmetically unacceptable alteration of the skin, and affects an estimated 85% to 98% 
of postpubertal women.( 1,3) 
The pathophysiol
ogy of EFP is not completely understood, but there are 3 main theories: edema 
resulting from excessive hydrophilia of the intercellular matrix, alteration of the regional 
microcirculation, and different anatomical conformation of collagenous subcutaneous tissues in 
women versus men.( 4) 
It is known t
hat EFP is different from generalized obesity. In generalized obesity, adipocytes 
undergo hypertrophy and hyperplasia that are not limited to the pelvis, thighs, and abdomen.( 1) 
In areas of EFP, 
adipocytes have physiologic and biochemical properties that differ from adipose 
tissue located elsewhere. Large, metabolically-stable adipocytes characterize EFP-prone areas; 
thus, the responsiveness to catecholamine-induced lipolysis is less in EFP tissues compared to 
visceral fat, which has the greatest responsiveness.( 1) 
Subcutaneous fat lobes are separated from one another by [CONTACT_101496], usually rigid strands of 
collagenous connective tissues, which cross the fatty layers and connect the dermis to the 
underlying fascia. These septa stabilize the subcutis and divide the fat. In EFP, shortening of the 
collagen septa due to fibrosis provokes retraction at the insertion points of the trabeculae, 
causing the depressions that characterize EFP. (2) There are a higher percentage of thinner, 
perpendicular
 hypodermal septa in women with EFP than in men.( 1) Weight gain makes EFP 
more noticeable, but 
it may be present even in thin subjects. Genetics may also play a role sinc e 
EFP tends to run in families. 
8.1.2. Current EFP Treatments  
There are therapi[INVESTIGATOR_596589]; however, there are no 
approved pharmacologic treatments. Despi[INVESTIGATOR_807553], there is little 
scientific evidence that any of these treatments are beneficial. In fact, much of the evidence is 
anecdotal, subjective, or based only on patient self-assessment.( 5) Some of the historical 
treatments for EFP have included weight loss, (6) topi[INVESTIGATOR_12450], (5) m assage, (7) liposuction (5,6) 
mesother
apy,( 6) radiofrequency,( 6) subcision and powered subcision, (8) and laser 
therap
ies;(9,10) some of these treatments may pose an increased risk for adverse effects (5). 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 19 
   There remains an unm
et medical need for safe and effective therapi[INVESTIGATOR_807554]. To effectively treat cellulite, a therapeutic approach may 
require disrupti
on of the dermal septa, which are composed of collagen and cause the skin 
dimpling that is bothersome to many women. 
8.1.3. EN3835 (Collagenase Clostridium Histolyticum) 
Endo Pharmaceuticals Inc. (Endo) i
s developi[INVESTIGATOR_742808]3835 for the treatment of EFP. Because 
EN3835 is a pr
oteinase that can hydrolyze the triple-helical region of collagen under 
physiological conditions, EN3835 has the potential to be effective in lysing subdermal collagen, 
such as those observed in the dermal septa, which are the underlying cause of the skin dimpling 
in women with EFP. EN3835 targets the collagenase structural matrix (eg, dermal septa) at the 
site of injection and does not require systemic exposure to be effectiv e. 
EN3835 is a parenteral lyophilized product comprised of 2 collagenases in an approximate 1:1 
mass ratio, Collagenase I (AUX-I, Clostridial class I collagenase) and Collagenase II (AUX-II; 
Clostridial class II collagenase). These collagenases are isolated and purified from the 
fermentation of Clostridium histolyticum . 
Collagenase
 AUX-I is a single polypeptide chain containing approximately 1,000 amino acids of 
known sequence and with a molecular weight of 114 kiloDaltons (kDa). Collagenase AUX-II is 
also approximately 1,[ADDRESS_1267643] collagen. 
Clostridial collagenases are proteinases that can hydrolyze the triple-helical region of collagen 
under physiological conditions. 
EN3835 is currently approved (brand name [CONTACT_807674]®) for: 1) the treatment of adults with 
Dupuytren’s contracture with a palpable cord and, 2) for the treatment of adult men with 
Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the 
start of therapy. 
A recent Phase 2b, randomized, double-blind, placebo-controlled study (EN3835-201) of 
375 women randomized to treatment of one treatment area (quadrant) (quadrant was defined in 
study EN3835
-201 as a left buttock, a right buttock, a left posterolateal thigh or a right 
posterolateral thigh) of cellulite with EN3835 0.84mg or placebo in a 1:1 ratio assessed the 
effectiveness and safety of EN3835. Efficacy in this study was evaluated based on cellulite 
assessments using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS), 
Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS), Investigator Global 
Aesthetic Improvement Scale (I-GAIS), Subject Global Aesthetic Improvement Scale (S-GAIS), 
and Subject Satisfaction with Cellulite Treatment. 
Results from the Phase 2b study demonstrated that treatment (3 visits approximately 21 days 
apart) improved the cellulite severity of the treated quadrant as assessed by [CONTACT_903765] 2-level composite responder analyses, the proportion of responders based on an improvement 
of ≥2 level
 in the appearance of cellulite in both the patient PR-PCSS and the clinician CR-PCSS 
of buttocks and thighs was statistically significantly greater in subjects who received EN3835 
0.84 mg (10.6%; p<0.001) compared to subjects who received placebo (1.6%); 1-level (or 
greater) 
responders in the PR-PCSS of EN3835-treated subjects (72.3%) was significantly 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 20 
   greater than 1
-level responders in the placebo group (51.6%) (p<0.001); statistically significant 
(p≤0.001) improvement in the appearance of cellulite based on the subject S-GAIS were 
observed in EN3835 0.84-mg group (73.1%) compared to the placebo group (44.0%); and 
sixty-two percent (62.9%) of subjects in the EN3835 0.84mg group were satisfied or very 
satisfied with the results of their cellulite treatment compared with only 35.9% of subjects in the 
placebo group (p<0.001). In subjects treated in buttocks (n=187), the proportion of 2-level 
composite responders was statistically significantly greater in subjects who received EN3835 
0.84 mg (14.9%; p<0.001) compared to subjects who received placebo (1.1%); 1-level (or 
greater) responders in the PR-PCSS of EN3835-treated subjects (72.7%%) was significantly 
greater than 1-level responders in the placebo group (47.8%) (p<0.001). 
The study also demonstrated EN3835 to be well tolerated with no serious adverse events (SAEs) 
related to EN3835. Safety results from a total of four studies (1 pi[INVESTIGATOR_2268], 2 Phase 1, and 2 Phase 2 
studies) in whic
h 435 adult females received subcutaneous injections of EN3835 indicate that the 
majority of TEAEs are transient, non-serious, mild or moderate in intensity, and related to the 
local administration of EN3835. The immunogenicity profile after 3 treatment visits of EN3835 
indicate 100% of EN3835-treated subjects were seropositive for AUX-I and/or AUX- II 
antibodi
es; this profile of EN3835 is similar to that observed in the Dupuytren’s contracture and 
Peyronie’s disease programs. 
A Phase 1, open-label, safety and pharmacokinetic study of a single dose of EN3835 0.84mg in 
11 femal
e subjects with EFP showed that there was no quantifiable levels of AUX-I or AUX- II 
at any timepoint after subcutaneous injection of EN3835 0.84mg into one quadrant. A second 
Phase 1, open-label, safety and pharmacokinetic study of a single dose of EN3835 0.84mg per 
treatment area in two treatment
 areas (buttock-buttock, thigh-thigh, or buttock-thigh) 
concurrently (total dose of 1.68mg) showed that there was no quantifiable levels of AUX-I or 
AUX-II at any timepoint post-dose attributable to the injection of EN3835 1.68mg. 
The results from these studies suggest that subcutaneous injections of EN3835 in the area of 
cellulite may be a well-tolerated and effective medical treatment for adults with EFP. 
8.2. Su
mmary of Nonclinical Studies 
Non-clinical studies necessary to support clinical studies have been performed and are 
summarized in the Investigator Brochure (IB). (11) Non-clinical studies in the following areas 
were perform
ed: toxicology, reprotoxicity, genotoxicity, and hypersensitivity. 
8.3. Summary of Known Risks and Benefits 
A summary of safety risks is provided in the IB.( 11) The following events have been commonly 
observed: lo
cal injection site reactions (injection site bruising, injection site swelling, and 
injection site pain) for the various approved indications as well as those being investigated. In the 
phase 2b study of EN3835 in women with EFP, the following treatment-related adverse events 
≥2% of 189 EN3835-treated women were reported: injection site bruising (75.1%), injection site 
pain (59.3%), injection site nodule (14.3%), injection site pruritus (11.1%), injection site 
swelling (7.4%), injection site induration (5.8%), injection site mass (5.3%), injection site 
discolouration (3.2%), and injection site erythema (2.1%). These events are similar to events 
reported in the clinical trials of EN3835 for the approved indications. Post-marketing safety data 
have been consistent with data reported in clinical trials. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 21 
   Although a thorough benefit of EN3835 has not
 been fully evaluated in the treatment of EFP, th e 
efficacy results from the Phase 2b study and previous EFP studies warranted further 
development. 
8.4. Rationale 
The alterations found in EFP are due largely to fibrosis of the connective tissues in the dermis 
and/or subcutaneous tissues.( 2) Subcutaneous fat lobes are separated from one another by [CONTACT_101496], 
usually ri
gid strands of connective tissues, which cross the fatty layers and connect the dermis to 
the underlying fascia. These collagen septae stabilize the subcutis and divide the fat. Shortening 
and thick
ening of the septae due to fibrosis provokes retraction at the insertion points of the 
trabeculae, causing the depressions that characterize EFP.( 2) 
The pharma
cologic activity of EN3835 involves selective lysis of the triple-helical region of 
collagen under physiological conditions at the site of injection. EN3835 targets the collagenase 
structural matrix (eg, septae), which is the underlying cause of the skin dimpling, and does not 
require systemic exposure to be effective. The pharmacologic activity of EN3835 is local, rapid, 
and is ess
entially complete within 24 hours. 
The data from the Phase 2a EFP dose-ranging study (AUX- CC-831) suggest that EN3835 
0.[ADDRESS_1267644], although the EN3835 0.48 mg group did 
show improvement in some of the efficacy parameters. 
 There were no safety concerns following administration of up to 3 treatment sessions 
of EN3835 0.84 mg in the treatment of EFP (section [IP_ADDRESS]). The safety profile of 
EN3835 0.84 
mg in the treatment of EFP was similar to that observed in the EN3835 
0.06 mg group and the EN3835 0.48 mg group. No notable differences were observed 
across the
 3 treatment groups. 
 Safety findings from the  Phase 2a EFP dose-ranging study are similar to that 
observed in previous clinical studies with XIAFLEX in the treatment of Dupuytren’s 
contracture and Peyronie’s disease, in that that the majority of AEs occurred at the 
site of injection and resolved before the next scheduled treatment. 
 The immunogenicity profile of EN3835 in the Phase 2a EFP dose-ranging study is 
simil
ar to that observed in the Dupuytren’s contracture and Peyronie’s disease 
programs. 
 Based on the eff icacy and safety findings from the Phase 2a EFP dose-ranging study, 
the EN3835 0.84-mg dose was carried forward to this study. 
The results from the Phase 2b EFP study (EN3835-201) further suggested that EN3835 0.84 mg 
per treatment area (quadrant) is an effective treatment of EFP based on improvement in the 
severity of cellulite as determined by [CONTACT_535740]. There were no safety 
concerns following 0.84 mg in the treatment of EFP (section 8.1.3 ). Safety findings from the 
Phase 2b EFP study are s
imilar to that observed in previous clinical studies with EN3835 in the 
treatment of EFP and XIAFLEX in the treatment of Dupuytren’s contracture and Peyronie’s 
disease, in that that the majority of AEs occurred at the site of injection and resolved before the 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 22 
   next scheduled treatment
. The immunogenicity profile of EN3835 in the Phase 2b EFP study is 
similar in previous studies and programs. 
Based on the efficacy and safety findings from the Phase 2a and 2b EFP studies, the EN3835 
0.84-mg dose per treatment area in a region (buttocks or posterolateral thighs) warranted further 
investigation in this study. 
Treating two bilateral treatment areas of a region at each treatment visit will potentially provide a 
symmetrical-like improvement in appearance. Support for evaluation of the treatment of two 
treatment
 areas concurrently is based on: 1) the safety findings from the previous EFP studies are 
local to the injection site, 2) the pharmacological activity of EN3835 is local and does not require 
systemic exposure, and 3) no significant quantifiable systemic concentration has been 
attributable to injection of two buttocks concurrently. 
The integration of dose and use justification supports this study of evaluation of EN3835 
0.84-mg per treatment area in two treatment areas (a region) concurrently. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 23 
   9. OBJECTIVES 
9.1.
 Primary Objective 
The primary objective of this study is to assess the safety of EN3835 in the treatment of 
edematous f
ibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women. 
9.2. Secondary Objective 
The secondary objective of this study is to assess the effectiveness of EN3835 in the treatment of 
edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women. 
9.3. Exploratory Objectives 
There are no exploratory objectives of this study. 

EN3835-[ADDRESS_1267645] of 3 treatment visits, 21 days apart. Subjects meeting the entry 
criteria for this study will receive EN3835 treatment within an investigational site and assigned 
region (ie, bilateral buttocks or bilateral thighs) on Day 1, Day 22, and Day 43, and will be 
followed for up to [ADDRESS_1267646] day of treatment. Subjects will receive follow-up visits 
at 1, 3, 6, and 13 days after each treatment course (either by [CONTACT_14223], for subjects participating 
in the photographic sub-study, in the clinic), and 2 follow-up visits at Day 90 and Day 180 to 
assess treatment effectiveness. The study also includes a photographic sub-study (conducted at 
two sites) in which subjects will return to the clinic for photographs at 1, 3, 6, and 13 days after 
each tre
atment course to coincide with the follow up visits. Sites participating in the 
photographic sub-study will also follow subjects for the same 180-day period. 
The complete schedule of events is provided in section 5. 
Figure 1: 
Study Design 
 
Table 
3:  Study Treatment Groups 
Dose per 
Each  Injectiona / 
Number of 
Subjects  Injection 
Volume per 
Each 
Injection  Number of 
Injections at Each 
Treatment Visit  Dose (mg) at Each 
Treatment Visit  Injection 
Volume (mL) 
per Each 
Treatment 
Visit   
Cumulative EFP 
Dose  
EN3835 0.07 mg / 
N=up to 150 0.3 mL 12 per treatment 
area x 2 treatment 
areas = 24  0.84 mg per 
treatment area x 2 
treatment areas =  
1.68 mg  
(12 injections per 
treatment area x 
0.07 mg/injection x 
2 treatment areas)  3.6 mL per 
treatment area 
x 2 treatment 
area = 7.2 mL  
(24 injections 
× 0.3 mL)  5.04 mg  
(3 treatment visits × 
0.84 mg per 
treatment area x 2 
treatment areas)  
a Each injection of study drug is 0.3 mL administered as three 0.1 mL aliquots. 
10.2. Selection of Doses 
The dose of EN3835 chosen for this study was based on the experience from earlier studies. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 25 
   The data from the Phase 2a EFP dose-
ranging study (AUX- CC-831) sugg est that EN3835 
0.[ADDRESS_1267647], although the EN3835 0.48-mg 
group did show improvement in some of the efficacy parameters. 
 There were no safety concerns following administration of up to 3 treatment visits of 
EN3835 0.8
4 mg in the treatment of EFP (AUX- CC-831 CSR). The safety profile of 
EN3835 0.84 
mg in the treatment of EFP was similar to that observed in the EN3835 
0.06-mg group and the EN3835 0.48-mg group. No notable differences were 
observed acro
ss the 3 treatment groups. 
 Safety findings from the  Phase 2a EFP dose-ranging study are similar to that 
observed in previous clinical studies with XIAFLEX in the treatment of Dupuytren’s 
contracture and Peyr
onie’s disease, in that the majority of AEs occurred at the site of 
injection and resolved before the next scheduled treatment. 
 The immunogenicity profile of EN3835 in the Phase 2a EFP dose-ranging study is 
simil
ar to that observed in the Dupuytren’s contracture and Peyronie’s disease 
programs. 
 Based on the efficacy and safety findings from the Phase 2a EFP dose-ranging study, 
the EN3835 0.84-mg dose was carried forward to a Phase 2b study (EN3835-201). 
The results from the
 Phase 2b EFP study (EN3835-201) further suggested that EN3835 0.[ADDRESS_1267648]. There were no safety concerns following EN3835 0.84 mg 
in the treatment of EFP (section 8.4). Safety findings from the Phase 2b EFP study are similar to 
that observed in pr
evious clinical studies with XIAFLEX in the treatment of Dupuytren’s 
contracture and Peyronie’s disease, in that that the majority of AEs occurred at the site of 
injection and resolved before the next scheduled treatment. The immunogenicity profile of 
EN3835 in the Phase 2b EFP study is similar to that observed in the Dupuytren’s contracture 
and Peyronie’s disease programs. 
Based on the efficacy and safety findings from the Phase 2a and 2b EFP studies, the EN3835 
0.84-mg dose per treatment area was carried forward to this study. The findings from previous 
studies that the m
ajority of adverse events after EN3835 treatment are local to the injection site 
and that there is no quantifiable systemic exposure observed after concurrent treatment of two 
treatment areas (total dose of 1.68 mg) supports the proposed study to evaluate EN3835 
treatment of two treatment areas. 
10.3. Study Drug Administration 
Study drug will be injected subcutaneously while the subject is in a prone position using a 
syringe with a 30-gauge ½ -inch needle. Each injection site will receive a single skin injection of 
study drug administered as three 0.1-mL aliquots to Positions A, B, and C (for a total injection 
volume of 0.3 mL) as shown in Figure 2. The depth of injection corresponds to the length of the 
treatment
 needle (0.5 inches) from the tip of the needle to the hub or base of the needle without 
downward pressure. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 27 
   NOTE: EN3835 is a fore
ign protein and Investigators should be prepared to address and manage 
an allergic reaction should it occur. At the time of each injection, a 1:1,[ADDRESS_1267649]’s 
vital signs should be stable before the subject can leave direct observation (see section 14.9).  
The Investigat
or or qualified designee will then apply a sterile dressing to the injection areas 
with hypoallergenic tape. The subject will be instructed to remove the dressing in the evening. 
10.5. Discussion of Study Design, Including the Choice of Control Groups 
The design of this study was based on the primary objective to assess the safety of EN3835 
0.84 mg per treatment area in the concurrent treatment (total dose of 1.68 mg) of EFP in a 
treatment
 region (bilateral buttocks or bilateral posterolateral thigh) in adult women. It is an 
open-label study. 

EN3835-[ADDRESS_1267650] meet the following criteria: 
1. Voluntarily sign and date an informed consent agreement 
2. Be a f
emale ≥[ADDRESS_1267651] 2 bilateral treatment areas with each treatment area 
having: 
a. a score of 2 
(mild) or greater as reported by [CONTACT_737] (CR-PCSS), and 
b. a Hexsel CSS score no greater than [ADDRESS_1267652]
udy (ie, Screening through end-of-study) 
5. Be judged to be i n good health, based upon the results of a medical history, physical 
examination, and laboratory profile at Screening 
6. Have a negative ser um pregnancy test at Screening and a negative urine pregnancy test 
before injection of study dr
ug and be using a stable and effective contraception method 
(eg, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, 
or double barrier method) for at least 1 menstrual cycle prior to study enrollment and for 
the duration of the study; or be menopausal defined as 12 months of amenorrhea in the 
absence of othe
r biological or physiological causes, as determined by [CONTACT_737]; or 
post-menopausal for at least 1 year; or be surgically sterile 
7. Be willing and able to cooperate with the requirements of the study  
8. Be able t
o read, complete,  and understand the patient-reported outcomes rating 
instruments in English  
11.2. Subject Exclusion Criteria 
Subjects who meet any of the following criteria will not be eligible to participate in the study: 
1. Has any of the following systemic conditions: 
a. Coagulation disorder 
b. Evidence or history of malignancy (other than excised basal-cell carcinoma) unless 
there
 has been no recurrence in at least [ADDRESS_1267653]’s well-being. 
Any questions about concurrent diseases should be discussed with the Medical 
Monitor. 
e. Evidence of clinically significant abnormalities on physical examination, vital signs, 
electrocardiogram (ECG), or clinical laboratory values 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 29 
   2. Has any of the following local conditions in the area t o be treated: 
a. History of lower extremity thrombosis or post-thrombosis syndrome 
b. Vascular disorder (eg, varicose veins, telangiectasia) in area to be treated 
c. Inflamm
ation or active infection 
d. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer 
e. Has a tattoo and/or a mole located within 2 cm of the site of injection 
3. Requires the following concomitant medications before or during participation in the 
trial:
 
a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet 
medication (except for ≤150 mg aspi[INVESTIGATOR_34223]) within 7 days before injection of study 
drug 
4. Has used any of the f ollowing for the treatment of EFP on the legs or buttocks within the 
timelines identified below or intends to use any of the following at any time during the 
course of the study: 
a. Liposuction in the areas of the body selected for treatment during the 12-month 
period before injection of study drug 
b. Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; 
buttock and
/or thigh implant treatment; or surgery (including subcision and/or 
powered subcision) within the assigned treatment areas during the 12-month period 
before injection of study drug 
c. Endermologie, cryolipolysis or similar treatments within the assigned treatment areas 
during the 6-month period before injection of study drug 
d. Massage therapy within the assigned treatment areas during the 3-month period 
before inject
ion of study drug 
e. Creams (eg, Celluvera™, TriLastin®) to prevent or mitigate EFP within the assigned 
treatment areas during the 2-week period before injection of study drug 
5. Is presently nursing a baby [CONTACT_903766] 
6. Int
ends to become pregnant during the study 
7. Int
ends to initiate an intensive sport or exercise program during the study 
8. Int
ends to initiate a weight reduction program during the study 
9. Intends to use tanning spray or tanning booths during the study 
10. Has received an investigational drug or treatment within [ADDRESS_1267654] in a previous cellulite clinical trial of collagenase clostridium histolyticum 
(CCH):
 AUX -CC-830, AUX- CC-831, EN3835-102, EN3835 -104, EN3835-201, and/or 
EN3835-202 
14.
 Any other condition(s ) that, in the Investigator’s opi[INVESTIGATOR_1649], might indicate the subject to be 
unsuitable for the study 

EN3835-[ADDRESS_1267655] who signed informed consent ceases 
participation in the study, regardless of circumstances, prior to the completion of the protocol. 
Subjects can be prematurely discontinued from the study for one of the following reasons: 
 An adverse event  
 A protocol viol ation (reason must be specified, for example: lack of compliance, use 
of a prohibited concomitant medication, failure to meet inclusion/exclusion criteria 
after study entry, etc.) 
 Withdrawal by [CONTACT_1130] (reason must be specified) 
 The subject 
was “lost to follow-up” 
 Other reasons (reason must be specified, for example: the subject moved, pregnancy, 
Investigat
or decision, Sponsor decision to terminate trial, etc.) 
If a subject discontinues from the study, all end- of-study procedures should be conducted as 
detailed in section  5, Schedule of Events. The date a subject discontinues and the reason for 
discontinua
tion will be recorded in the source documentation and Electronic Case Report Form 
(eCRF). If, however, a subject withdraws consent, no end-of-study procedures are required (but 
are encouraged to reduce missing information) except the collection of adverse event (AE) 
information. This information should be recorded in the source documentation and the eCRF. 
11.3.1. Replacement Procedures  
Subjects who discontinue from the study will not be replaced. 

EN3835-[ADDRESS_1267656] and the date and outcome of the 
screening process (eg, enrolled into the study, reason for ineligibility, or refused to participate). 
Investigators will provide information about the study to subjects who appear to meet the criteria 
for participation in the study. The screening log will be captured directly by [CONTACT_27950]. 
[IP_ADDRESS].  Medical History 
During the screening period, the Investigator or qualified designee will obtain a medical history 
from each subject that includes relevant diagnoses and/or procedures/therapi[INVESTIGATOR_742802]/resolutions dates. Medical histories should also include history of EFP (start date and 
family history), and history of tobacco and alcohol use (never, current, former). 
[IP_ADDRESS].  Screening Period (Day -14 to Day -1) 
Subjects m
eeting the relevant eligibility criteria listed in section [ADDRESS_1267657] number. 
The following proce
dures will be performed and documented during the screening period: 
1. Obtain written informed consent (section  12.1.1 ) 
2. Evaluat
e eligibility based on inclusion/exclusion criteria (sections  11.1 and 11.2) 
3. The Investigator will conduct live assessments of subject’s cellulite severity of the 
4 treatment areas using the CR -PCSS (section  13.1.1); the subject is blinded to these 
ratings 

EN3835-[ADDRESS_1267658] 
live c
ellulite evaluation of the 4 treatment areas using the Hexsel CSS. The ratings from 
the CR-
PCSS and Hexsel CSS (section 13.1.3  ) will be used to assess initial eligibility of 
trea
tment areas for study entry. 
5. If eligible based on CR-PCSS, and Hexsel CSS ratings, random assignment of a 
treatment
 region (two bilateral treatment areas) for treatment (section  [IP_ADDRESS])  
6. Medical history including EFP history (section  [IP_ADDRESS] ) 
7. Record prior and concomitant medications/procedures (section  12.9) 
8. Physical examination including measurement of body weight, height, Fitzpatrick skin 
type (
section 14.11)  
9. Vital sign measurements (section  14. 9) 
10. 12-lead electrocardiogram (ECG) (section  14.10 ) 
11. Collec
tion of samples for: 
a. Clinica
l laboratory testing (section  14.7)  
b. Serum pregnancy testing (section  14.7) 
12. Adverse events (section 14) 
[IP_ADDRESS].  Assignm
ent of Treat
ment Areas 
Subjects must have at least 1 eligible treatment region (eg, 2 bilateral treatment areas) that meet 
the following criteria for inclusion into the study: 
 CR-PCSS score of 2 or greater in each treatment area, and 
 Hexsel CSS score no greater than 13 in either treatment area. 
Assignment
 of the treatment region will be chosen randomly by [CONTACT_697334] 
(IWRS) from the regions meeting the above inclusion criteria. If no two bilateral 
treatment
 areas meet the criteria, the IWRS will inform the site that the subject does not have 
treatment
 regions that qualify for the study. 
12.2. Selecting and Marking Dimples during Treatment 
Selection of dimples to be treated in the two assigned treatment areas is at the discretion of the 
Investigator. Dimples must be well-defined and evident when the subject is standing in a 
consistent relaxed pose (without the use of any manipulation such as skin pi[INVESTIGATOR_596600]). Each subject will receive 3 treatment visits of study drug unless the treatment area 
is dimple-free (score of 0 on CR-PCSS as reported by [CONTACT_737]). 
Treatment
 consists of 12 injections per treatment area (total 24 injections) per visit. Because the 
goal of treatment is to improve the aesthetic appearance of each entire treatment area, the 
Investigator will be instructed to select dimples that in his/her opi[INVESTIGATOR_903761]. The same dimples within a treatment area or 
different dimples within a treatment area may be treated at each visit but injections must all be 
within the assigned treat
ment area for all 3 visits. Each treatment area will receive all 3 treatment 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 33 
   visits unless the assigned treatment area has no tre
atable EFP dimples and the Investigator rates 
the treatment area a score of 0 on the CR-PCSS. If no injections in a particular treatment area are 
given at Treatment Visit 2, subjects will still be assessed for treatment in the contralateral 
treatment area at Treatment Visit 2, and will return for the Day 43 visit and the assigned 
treatment
 areas will again be evaluated by [CONTACT_737] (CR-PCSS). If the Investigator rates 
either or both of the assigned treatment areas greater than 0 on the CR-PCSS, injections at 
Treatment Visit 3 should be given. 
At each treatment visit, prior to selecting and marking dimples, sites participating in the 
photography sub-study should photograph the selected treatment areas. For each dimple selected 
for treatment, the Investigator or qualified designee will choose injection sites (injection sites 
within a dimple should be spaced approximately 2 cm apart, if a dimple requires more than 
1 injection; locating at least one injection site at the nadir, if present, of the dimple). Each 
injection site wil
l be marked with a “dot” using a surgical marker. For round dimples, the “dot” 
will be placed in the center of the dimple; for elongated dimples, “dots” will be spaced out 
approximately [ADDRESS_1267659] each of the dimples selected for treatment. Circles in the 
assigned treatment area should not overlap (Figure 3 ). Sites participating in the photographic 
sub
-study (section 12.12 ) will be instructed to obtain photographs of the subject’s marked 
treatment areas prior to injection on the visit days that require treatment (section 5). 
Figure
 3: Examples of Subject Dimple and Injection Site Markings 
Sample T high Marking  Sample Buttock Marking  
  
12.3. Treatment Visit 1 (Day 1) 
12.3.1. Treatment Visit 1: Pre-Injection 
1. For eligible treatment areas, obtain kit numbers of study treatment and reconstitute drug 
product using aseptic technique 
2. Record concomitant medications/procedures (section  12.9)  
3. Vital sign measurements (section  14.9 ) 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 34 
   4. Collection of samples for: 
a. Anti- AUX
-I and an ti-AUX-II antibody testing (section  14.8 ) 
b. Urine pregnancy testing (section  14. 7) 
5. Digital photographs of each treatment area before marking dimples and injection sites 
(NOTE: Thi
s is ONLY for sites participating in the photographic sub-study.) 
6. Select and mark dimples to be treated in each of the assigned treatment areas 
(s
ection  12.2)  
7. Digital photographs of each treatment area after marking dimples and injection sites 
(section 12.12 ) 
12.3.2. Treatment Visit 1: Injection and Post-injection 
1. Ad
ministration of study drug in the prone position (section  1 0.3) 
2. Record number of dimples t reated and number of injections administered in each of the 
two assigned treatment areas 
3. Vital sign measurements (section  14. 9) 
4. Injection site reactions and local tolerability 
5. Adverse
 events (section 14) 
12
.4. Follow
-up Visits at 1, 3, 6, and 13 Days Following Each Treatment 
Visit 
12.4.1. For Sites Participating in the Photographic Sub-study (section 12.12 ) 
1. Any changes i
n concomit ant medications or procedures 
2. Injection site reactions and local tolerability 
3. Adverse
 events (section 14) 
4.
 Digital photographs of each treatment area 
12.4.2. For S
ites not Participating in the Photographic Sub-study 
1. Any changes in concomit ant medications or procedures 
2. Injection site reactions and local tolerability 
3. Adverse
 events (section  14) 
12.5. Treatment Visit 2 (Day 22 [±3 days]) and Treatment Visit 3 (Day 43 
[±3 days]) 
12.5.1. Treatment Visits 2 and 3: Pre-injection 
1. Record concomitant medications/procedures (section  12.9)  
2. Body weight measurement 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 35 
   3. Vital sign measurements (section  14. 9) 
4. Collection of samples for: 
a. Anti- AUX
-I and anti- AUX-II antibody testing (section  14.8 ) 
b. Urine pregnancy testing (section  14. 7) 
5. Digital photographs of each treatment area before marking dimples and injection sites 
(NOTE: Thi
s is ONLY for sites participating in the photographic sub-study.) 
6. Investigator Cellulite Assessments of each of the assigned treatment areas prior to 
mar
king dimples and injection sites using: 
a. Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) live assessment 
of subject (section  13.1.1)  
7. Select and mark dimples to be treated in each assigned treatment areas (section  12.2 ) 
8. Digital photographs of each buttock after marking dimples and injection sites 
(section  12.12 ) 
12.5.2. Treatment Visits 2 and 3: Injection and Post-injection 
1. For el
igible assigned treatment area(s), obtain kit number(s) of study treatment and 
reconstit
ute drug product using aseptic technique. 
2. Administration of study drug in the prone position (section  1 0.3) 
3. Record number of dimples t reated and number of injections administered in each 
assigned treatment area 
4. Vital sign measurements (section  14. 9) 
5. Injection site reactions and local tolerability 
6. Adverse
 events (section 14) 
12
.6. Day 90
 (±3 days) 
The following procedures will be performed on Day 90: 
1. Record concomitant medications/procedures (section  12.9 ) 
2. Measurement of body weight 
3. Vital sign measurements (section  14.9 ) 
4. Collection of samples for: 
a. Anti- AUX-I and anti- AUX-II antibody testing (section  14.8 ) 
b. Urine pregnancy testing (section  14. 7) 
5. Investigator Cellulite Assessments of each of the assigned treatment areas using: 
a. Clinic
ian Reported Photonumeric Cellulite Severity Scale (CR-PCSS) live assessment 
of subject (section  13.1.1)  

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 36 
   6. Injection site reactions and local tolerability 
7. Adverse
 events (section 14) 
12
.7. Day 18
0 (+7 days) End- of-Study / Early Termination 
The following procedures will be performed on Day 180: 
1. Measurement of body weight 
2. Vita
l sign measurements (section  14. 9) 
3. Collection of samples for: 
a. Clinical laborator
y testing (section  14.8)  
b. Anti- AUX- I and anti- AUX-II antibody testing (section  14.7 ) 
c. Serum pregnancy testing (section  14.7)  
4. Subject Cellulite Assessment using: 
a. Subject Sa
tisfaction with Cellulite Treatment Assessment (section  13.1.2 ) 
5. Inve
stigator Cellulite Assessments of each of the assigned treatment areas using: 
a. Clinic
ian Reported Photonumeric Cellulite Severity Scale (CR-PCSS) live assessment 
of subject (section  13.1.1)  
6. Injection site reactions and local tolerability 
7. Adverse
 events (section 14) 
[ADDRESS_1267660] additional study 
procedures if required. 
12.9. Prior and Concomitant Medications and Procedures 
All prior medications taken within 90 days before Day 1 will be recorded. All medications 
(including over-the-counter medications) taken by [CONTACT_26259] [ADDRESS_1267661] be recorded. Any prior treatments (medications or procedures) for EFP through the 
end of the study must be recorded on the appropriate eCRF page. 
Additionally, any diagnostic, therapeutic or surgical procedures performed during the study 
period should be recorded including the date, indication for and description of the procedure. 
12.9.1. Prohibited Medic ations or Procedures 
The following medications are prohibited for randomized subjects during the study: 
anticoagulants (warfarin, heparin, direct thrombin inhibitors, Factor X inhibitors) and antiplatelet 
agents (aspi[INVESTIGATOR_248] >150 mg/day and P2Y12 inhibitors, such as clopi[INVESTIGATOR_7745]), which can cause 
additional bruising. However the use of aspi[INVESTIGATOR_9601] a dose level of ≤150 mg per day will be 
permitted during study. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 37 
   Procedures listed 
in exclusion criterion #4 (section 11.2, Exclusion Criterion# 4) are prohibited 
for subjects during th
e study. 
Table 4: Concomitant Medication Restrictions for Subjects During the Treatment 
Phase of Study 
Drug Class  Restrictions  
Anticoagulants  Subjects cannot take antiplatelet agents or anticoagulants (except for ≤150  mg aspi[INVESTIGATOR_34223]) 
within 7  days before and 7 days after the dosing administration.  
12.10.  Treatment Compliance 
Subjects will receive study drug administered by [CONTACT_903767]’s site.  
Accidental or i
ntentional overdoses should be reported to the Sponsor/designee promptly (see 
section [IP_ADDRESS], Overdose). 
12.11.  Blind
ing and Randomization 
This is an open-label study. Each subject will have one or two regions (bilateral buttocks and/or 
thighs) eligible for treatment. If two regions are eligible, the IWRS will randomly assign each 
subject a treatment region. 
12.12.  Photographic Sub- study  
Two (2) or more sites will participate in a photographic sub-study designed to capture 
photographic reco
rds of subjects’ progression through the study treatment. In the sub-study, the 
treatment areas will be photographed before and after dimple marking while the subject is 
standing in a consistent relaxed pose as described in the Photography Manual. Subjects will be 
instructed to return to the clinic for follow-up photographs at 1, 3, 6, and 13 days after each 
treatment
 visit. 
12.13.  Medical Status Follow-up 
Subjects will be contact[INVESTIGATOR_530] (either by [CONTACT_756], or in person for subjects participating in the 
Photographic Sub-study) at 1, 4, 8, and 14 days after each treatment visit to provide updates on 
their medical status following treatment. Specific updates to medical status will include: 
1. Any changes in concomit ant medications or procedures 
2. Injection site reactions and local tolerability 
3. Adverse events (section 14) 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 38 
   13. ASSESSMENT OF EFFEC
TIVENESS 
13.1. Effectiveness Measurements 
13.1.1.  Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) 
The CR-PCSS will be conducted for the purpose of assessing the severity of cellulite in the 
buttock or thigh; there are separate scales for buttocks or thighs. The scales are 5-level 
photonumeric scales developed specifically for clinicians and used by [CONTACT_903768]’s cellulite in each treatment area by [CONTACT_260645]; the ratings range 
from 0 (None) to 4 (Severe) with labels and descriptors to aid the Investigator in the assessments. 
Investigators will be trained and qualified on the use of the CR-PCSS p rior to assessing any 
subjects. 
At the Screening visit, the Investigator will determine severity of cellulite of each of the 
4 treatment areas by [CONTACT_903769]-PCSS for buttock ( Appendix B) or thigh 
(Appendix C ). Before injections on treatment visits Day  1, Day 22, and Day 43, and on vis it 
Day 90 and Day
 180, Investigators will evaluate each of the two assigned treatment areas via live 
assessm
ent. If the buttocks are the treated region, the Investigator will use the CR-PCSS for the 
buttock to make his/her evaluation; if the thighs are the treated region, the Investigator will use 
the CR-
PCSS for the thigh to make his/her evaluation. 
13.1.2.  Subject Satisfaction with Cellulite Treatment Assessment 
At the Day [ADDRESS_1267662] represents their answer. 
For subjects that had buttocks treated: 
Today, how satisfied are you with the results of the cellulite treatment you received on the 
specific area or areas on your buttocks that were treated? 
Table 5: Subject Satisfaction with Cellulite Treatment Assessment - Buttocks 
Rating  Description  
+2 I am very satisfied with the cellulite treatment on my buttocks.  
+1 I am satisfied with the cellulite treatment on my buttocks.  
0 I am neither dissatisfied nor satisfied with the cellulite treatment on my buttocks.  
-1 I am dissatisfied with the cellulite  treatment on my buttocks.  
-2 I am very dissatisfied with the cellulite treatment on my buttocks.  
Or 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 39 
   For subjects that had 
thighs treated: 
Today, how satisfied are you with the results of the cellulite treatment you received on the 
specific area or areas on your thighs that were treated?  
Table 6
: Subject Satisfaction with Cellulite Treatment Assessment - Thighs 
Rating  Description  
+2 I am very satisfied with the cellulite treatment on my thighs.  
+1 I am satisfied with the cellulite treatment on my thighs.  
0 I am neither dissatisfied nor satisfied with the cellulite treatment on my thighs.  
-1 I am dissatisfied with the cellulite treatment on my thighs.  
-2 I am very dissatisfied with the cellulite treatment on my thighs.  
13.1.3.  Hexsel Cellulite Severity Scale 
The Hexsel Cellulite Severity Scale (referred to as the Hexsel CSS) is a photonumeric scale that 
looks at 5 key morphologic features of cellulite: (A) number of evident depressions, (B) depth of 
depressions, (C) morphological appearance of skin surface alterations, (D) laxity, flaccidity or 
sagging of skin, and (E) current classification scale based on medical literature including 
Nürnberger and Müller.( 12,13) Each of these features is evaluated on a 4-level scale from a low 
of 0 to a hig
h of 3 as described in Table  7  (Appendix D  a nd Appendix E). The total score is the 
summation of all [ADDRESS_1267663] for 
Category E (classification scale by Nürnberger and Müller) ( 13) if the subject has no evident 
depressions, the subject should be asked to contract her gluteus muscles or the pi[INVESTIGATOR_903762] (by [CONTACT_21173][INVESTIGATOR_596602]) so the Investigator or 
qualified designee can differentiate between scores/grades of zero (0) or I. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 40 
   Table 7: Hexsel Cellulite Severity Scale 
A Number of evident depressions  0=none/no depressions  
1=a small amount: 1 -4 depressions are visible  
2=a moderate amount: 5 -9 depressions are visible  
3=a large amount: 10 or more depressions are visible  
B Depth of depressions  0=no depressions  
1=superficial depressions  
2=medium depth depressions  
3=deep depressions  
C Morphological appearance of skin 
surface alterations  0=no raised areas  
1=‘orange peel’ appearance  
2=‘cottage cheese’  appearance  
3=‘mattress’ appearance  
D Grade of laxity, flaccidity, or sagging 
skin 0=absence of laxity, flaccidity, or sagging skin  
1=slight draped appearance  
2=moderate draped appearance  
3=severe draped appearance  
E Classification scale by Nürnberger and 
Müllera 0 = zero grade = Grade or Stage 0 = There is no alteration of the 
skin surface.  
1 = first grade = Grade or Stage I = The skin of the affected area is 
smooth while the subject is standing or lying, but the alterations to 
the skin surface can be seen by [CONTACT_21173][INVESTIGATOR_620042].  
2= second grade = Grade or Stage II = The orange skin or mattress 
appearance is evident when standing, without the use of any 
manipulation (skin pi[INVESTIGATOR_596598]).  
3= third grade = Grade or Stage III = The alterations described in 
Grade or Stage II, are present together with raised areas and 
nodules.  
Source: Hexsel DM, Dal’Forno T, Hexsel CL. A validated photonumeric cellulite severity scale. J Eur Acad 
Dermatol Venereol.  2009;23(5):523-8. 
a Subjects should be evaluated in the standing position with relaxed gluteus muscles. However, if the subject has no 
evident depressions, they should be asked to contract their gluteus muscles or the pi[INVESTIGATOR_596604] (by 
[CONTACT_21173][INVESTIGATOR_596602]) in order to differentiate between grade/stage of zero (0) 
or I. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 41 
   14. ASSESSMENT OF SAFETY
 
14.1. Definitions 
14.1.1.  Adverse Events 
An adverse event (AE) is any unfavorable or unintended change in body structure (signs), body 
function (symptoms), laboratory result (eg, chemistry, ECG, X-ray, etc.), or worsening of a pre-
existing condit
ion associated temporally with the use of the study medication whether or not 
considered related to the study medication. Adverse events will be captured once a subject has 
signed the informed consent. AEs include: 
 Changes in the gener al condition of the subject 
 Subjective symptoms offered by [CONTACT_303406] 
 Object
ive signs observed by [CONTACT_62244] 
 All c
oncurrent diseases t hat occur after the start of the study, including any change in 
severity or frequency of pre-existing disease 
 All clinically relevant laboratory abnormalities or physical findings that occur during 
the study
 
A treatment-emergent AE (TEAE) is any condition that was not present prior to treatment with 
study medication but appeared following treatment, was present at treatment initiation but 
worsened during treatment, or was present at treatment initiation but resolved and then 
reappeared while the individual was on treatment (regardless of the intensity of the AE when the 
treatment was initiated). 
All AEs, including both observed or volunteered problems, complaints, signs or symptoms must 
be recorded on the AE page of the eCRF, regardless of whether associated with the use of study 
medicat
ion. This would include AEs resulting from concurrent illness, reactions to concurrent 
medication use, or progression of disease states (excluding the disease under study). A condition 
present at baseline that worsens after initiation of study treatment will be captured as an AE; the 
onset date will be the date the event worsened. The AE should be recorded in standard medical 
terminology when possible. 
14.1.2. Serious Adverse Events 
A serious ad
verse event (SAE) is defined as an AE that: 
 Results in death 
 Is immediately life-threatening (there is an immediate risk of death from the AE as it 
occurred; this does not include an AE that had it occurred in a more serious form may 
have caused death) 
 Results in or prolongs an inpatient hospi[INVESTIGATOR_059] (Note: a hospi[INVESTIGATOR_596605]-planned surgery, procedure, or drug therapy does not constitute an SAE)  

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 42 
    Results in permanent or substantial disability (permanent or substantial disruption of 
one’s ability
 to conduct normal life functions)  
 Is a congenital anomaly/birth defect (in offspring of a subject using the study 
medi
cation regardless of time to diagnosis) 
 Is considered an important medical event 
Import
ant medical events are defined as events that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
other serious outcomes. Examples of important medical events include malignancy, allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse.  
14.2. Monitoring Adverse Events 
At each visit, subjects will be queried regarding any AEs that have occurred since the last visit. 
Subjects will be asked to volunteer information concerning AEs with a non-leading question 
such as, “How do you feel?” Study site personnel will then record all pertinent information in the 
source documents and the eCRF. The study drug compliance record should also be reviewed to 
detect potential overdoses (intentional/unintentional). 
14.3. Relationship to Study Drug 
The degree of “relatedness” of the AE to the study medication must be described using the 
following scale:  
 Not related  indicates that the AE is definitely not related to the study medication. 
 Unlikely related  indicates that there are other, more likely causes and study 
medication is not suspected as a cause. 
 Possibly related indicates that a direct  cause and effect relationship between study 
medication and the AE has not been demonstrated, but there is evidence to suggest 
there is a reasonable possibility that the event was caused by [CONTACT_7860]. 
 Probably related  indicates that there is evidence suggesting a direct cause and effect 
relationship between the AE and the study medication. 
It is the Sponsor’s policy to consider “Probably related” and “Possibly related” causality 
assessments as positive causality. “Not related” and “Unlikely related” causality assessments are 
considered as negative causality. 
Assessments will be recorded on the eCRF and must indicate clearly the relationship being 
assessed. For example, an AE that appears during a placebo run-in phase would be assessed with 
respect to the placebo treatment received and/or study procedures conducted during this phase. If 
the AE continued into an active treatment phase, the relationship would be assessed for the active 
treatment phase only if the AE worsened. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 43 
   14.4. Intensity 
Assessment 
The intensity (or severity) of AEs is characterized as mild, moderate, or severe: 
 Mild  AEs are usually transient, requiring no special treatment, and do not interfere 
with the subject’s daily activities. 
 Moderate  AEs introduce a low level of inconvenience or concern to the subject and 
may i
nterfere with daily activities, but are usually ameliorated by [CONTACT_39508]. 
 Severe  AEs interrupt a subject’s usual daily activity and typi[INVESTIGATOR_903763]. 
When the intensity category of an AE changes, the greatest intensity during that continuous 
epi[INVESTIGATOR_56218].  
14.5. Reporting Adverse Events and Serious Adverse Events 
14.5.1. Reporting Advers e Events 
Throughout the study, AEs will be documented on the source document and on the appropriate 
page of the eCRF whether or not considered treatment-related. This includes any new signs, 
symptoms, injury or illness, including increased severity of previously existing signs, symptoms, 
injury, or illness. Conditions existing prior to screening will be recorded as part of the subject’s 
medical history. The Investigator is responsible for assessing the relationship of AEs to the study 
medication; relationship will be classified as not related, unlikely related, possibly related, or 
probably related.  
All AEs will be collected by [CONTACT_596655] [ADDRESS_1267664] dose of study medication; this includes any AEs that are ongoing at 
the time of completion/termination of the study. All ongoing AEs must be followed until 
resolution or for [ADDRESS_1267665]’s last study visit, whichever comes first. 
14.5.2. Reporting Serious Adverse Events 
Any SAE, incl
uding death resulting from any cause, which occurs to any subject participating in 
this study must be reported via email or fax by [CONTACT_596656] [ADDRESS_1267666] is discontinued from the study.  The Investigator should 
report all pregnancies within 24 hours using the Initial Pregnancy Report Form, and any 
pregnancy-associated SAE using the SAE report form, according to the usual timelines and 
directions for SAE reporting provided in section 14.5.2 . Monitoring of the pregnancy should 
continue un
til conclusion of the pregnancy; 1 or more Follow-up Pregnancy Report Form(s) 
detailing progress, and a Two-Month Follow-up Pregnancy Report Form detailing the outcome, 
should be sub
mitted. 
Pregnancy itself is not regarded as an AE unless there is suspi[INVESTIGATOR_429001] a contraceptive medication. 
Likewise, elective abortions without complications are not considered AEs. Any SAEs 
associated with pregnancy (eg, congenital abnormalities/birth defects/spontaneous miscarriages 
or any other ser
ious events) must additionally be reported as such using the SAE report form. 
Spontaneous miscarriages should also be reported and handled as SAEs. 
A subject who becomes pregnant must be withdrawn from the study . Attempts to obtain the 
pregnancy follow-up and pregnancy outcome information detailed above are necessary even if a 
subject discontinues treatment because of pregnancy. 
14.6.4. AEs/SAEs Experienced by [CONTACT_51584]-subjects Exposed to Study Medication 
Non-
subjects are persons who are not enrolled in the study but have been exposed to study 
medication, including instances of diversion of study medication. All such AEs/SAEs occurring 
in non-subjects from such exposure will be reported to the Endo PVRM Department (when the 
non-subject agrees) on the departmental form for serious adverse experiences regardless of 
whether the 
event is serious or not. Instructions for completing the form for events experienced 
by [CONTACT_105]-subjects will be provided. SAEs occurring in non-subjects exposed to study medication 
will be processed wit
hin the same SAE reporting timelines as described in section  14.5.2, 
Reporting Ser
ious Adverse Events. Additionally, the drug accountability source documentation 
at the site should reflect this occurrence. 
14.7. Clinical Laboratory Determinations 
Clinical laboratory tests will be conducted according to the Schedule of Events (section 5). 
Clinical laboratory 
tests will be performed by a designated central laboratory . Each site will be 
provided with
 instructions on specimen collection, preparation, packaging and transport. Refer to 
the central laboratory manual for further information regarding sample collection, handling, and 
labeling. The results of the tests will be returned to the investigational sites.  

EN3835-205 Protocol 
31-Aug-2017 Endo Pharmaceuticals Inc. Page 46 
 Clinical laboratory tes
t data will be reviewed by [CONTACT_737], or designee, and additional 
clinical laboratory tests may be ordered at his/her discretion (eg, if the results of any clinical 
laboratory test falls outside the reference range or clinical symptoms necessitate additional 
testing to ensure safety). Any additional testing will be performed by [CONTACT_238512]. The Investigator or qualified designee must acknowledge the review of laboratory 
results. 
The Investigator will review all abnormal lab results for potentially clinically important. Any 
abnormal
 clinical laboratory test result meeting the Investigator’s criteria for potentially 
clinically important (refer to central laboratory manual) will be recorded as an AE or SAE as 
appropriate (see section 14.1.1 , Adverse Events, and section 14.1.2 , Serious Adverse Events). 
Laboratory results will be sent electronically to Endo Pharmaceuticals Inc. for data management. 
Clinical laboratory parameters that will be measured in this study are listed in Table 8. 
Table 8
: Clinical Laboratory Tests 
Hematology  Biochemistry  Urinalysis  
Hemoglobin  Glucose  Glucose  
Hematocrit  Sodium  Protein  
Red blood cell  Potassium  Specific gravity  
White blood cell (WBC)  Calcium  pH 
Platelets  Chloride  Ketones  
WBC Differential  CO 2 Bilirubin  
Inorganic phosphate  Urobilinogen  
Blood urea nitrogen Nitrite  
Creatinine  Blood*  
Creatinine clearance (estimated) Leukocytesa 
Aspartate transaminase (AST)  
Alanine transaminase (ALT)  
Gamma -glutamyl transferase (GGT)  
Total bilirubin (TBL) (direct bilirubin reflex if elevated)  
Albumin  
Alkaline phosphatase (ALP)  
Uric acid 
a Microscopic examination will be performed if blood or leukocytes are detected by [CONTACT_5230]. 
For women of childbearing potential, a serum pregnancy test will be performed at Screening and 
Day 180/End of Study/Early Termination, and any Unscheduled Visits. Urine pregnancy tests 
will be performed at Day 1, Day 22, Day 43, and Day 90 (refer to section  5). Female subjects of 
childbearing
 potential must have a negative pregnancy test at the Screening Visit and at Day 1 
(Baseline), Day 22, and Day [ADDRESS_1267667] kits will be supplied by [CONTACT_1034]. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 48 
   14.11.  Physical Examina
tion 
A complete physical examination will be performed at the Screening Visit. All examinations will 
be performed by a physician or health professional listed on the Form FDA 1572 and licensed to 
perform physical examinations. Height and body weight will be measured and recorded at 
screening. 
The Investigator will review all physical exam findings for clinical significance. Any physical 
exam finding 
meeting the Investigator’s or Sponsor’s criteria for clinical significance will be 
recorded as an AE or SAE as appropriate (see section  14.1.1, Adverse Events and section  14.1.2, 
Serious Adver
se Events). 
At screening, the Investigator will also assess the subject’s skin type using the Fitzpatrick scale 
(Table 10). Only the Fitzpatrick Scale shown below may be used during the study. 
Table 10: Fitzpatrick Scale 
I Pale white skin, blue/hazel eyes, blond/red hair  Always burns, does not tan  
II Fair skin, blue eyes  Burns easily, tans poorly  
III Darker white skin  Tans after initial burn  
IV Light brown skin  Burns minimally, tans easily  
V Brown skin  Rarely burns, tans darkly easily  
VI Dark brown or black skin  Never burns, always tans darkly  
Follow-up body weight will be measured before injection on Day [ADDRESS_1267668] Populations 
The following populations are considered in the statistical analysis of the study: safety, 
effectiveness and per-protocol (PP). 
17.2.1. Safety Population 
The safety population i
s defined as all enrolled subjects who have at least one injection of study 
medication. All safety parameters will be summarized based on this population. 
17.2.2. Effectiveness Population  
The effectiveness population is defined as all subjects in Safety Population with a baseline and at 
least [ADDRESS_1267669] one treatment area. All 
evaluati
ons of effectiven
ess will be based on the effectiveness population. 
17.2.3.  Per-Protocol (PP) Population 
Not applicable in the current study. 
17.3. Subject Disposition 
The number of subjects included in each study population will be summarized by [CONTACT_903770] (buttock or thigh) and overall. Subjects excluded from the safety and effectiveness 
populations will
 be listed. 
The number and percentage of subjects completed and prematurely discontinued during the 
treatment periods will be presented for each assigned region (buttock or thigh) and overall. 
Reasons for premat
ure discontinuation from the treatment period as recorded on the termination 
page of the eCRF will be summarized (number and percentage) by [CONTACT_903771]. 
17.4. Demographics and Other Baseline Characteristics 
The summarization of demographic variables (eg, age, sex, race, weight, height, and BMI), 
medical and surgical history, and other baseline characteristics relevant to the indication studied 
in the study will be presented. 

EN3835-[ADDRESS_1267670] deviation (SD), median, minimum and 
maximum for all continuous variables. 
17.5. Effectiveness Analyses  
17.5.1.  Effectiveness Variables 
 Proportion at each level of improvement in the CR- PCSS of e ach assigned treatment 
area (Day 22, Day 43, Day 90, and Day 180): 
 Proportion o
f responders defined as subjects with an improvement in severity 
from baseline of at least 2 levels of severity in the CR-PCSS 
 Proportion of responders defined as subjects with an improvement in severity 
from baseline of at least 1 level of severity in the CR-PCSS 
 Proportion of responses at each level of the subject satisfaction with cellulite 
treatm
ent (Day 180) 
All effect
iveness variables will be summarized as the number and percentages. 
Mean and standard dev
iation for changes in CR-PCSS from baseline will be summarized. 
17.6. Safety Analyses 
Safety variables include adverse events, laboratory parameters, vital signs, ECG (screening 
only), and physical examination. For each safety parameter, the last assessment made prior to the 
first dose of study drug will be used as the baseline for all analyses of that safety parameter. 
17.6.1.  Prior, Concomitant, and Follow-up Medication 
The World Health Organization (WHO) Drug Dictionary will be used to classify prior and 
concomitant medications by [CONTACT_18671]. Prior medication will be defined as any 
medication taken prior to the first dose of study drug. Concomitant medication is defined as any 
medication taken on or after the date of first dose of study drug. 
Prior and concom
itant medication use will be summarized descriptively by [CONTACT_807601] (generic name [CONTACT_807675]) by 
[CONTACT_3148]. Multiple use of the same medication by a subject will be counted only once. 
17.6.2.  Study Drug Exposure 
The following information regarding treatment will be summarized per each treated area: 
 Total number of treatment visits 
 Number of subjects who had treatment visit done or treatment visit not done at each 
treatm
ent day 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 53 
    For subjects who had the treatment visit done, the number of subjects who got all 
12 injection
s per treatment area 
 Number of injections given at each treatment visit 
 Nu
mber of dimples treated at each treatment visit 
 Average num
ber of injectio ns per dimple at each treatment visit 
Subjects who did not
 receive all three treatment visits and who did not receive a total of 
24 injections at a treatment visit will be listed. 
17.6.3. Measurement of Treatment Compliance 
Not applic
able (The study drug is administered at the site by [CONTACT_181258]). 
17.6.4. Adverse Events 
The Medical
 Dictionary for Regulatory Activities (MedDRA) will be used to code AEs. 
An AE (classified by [CONTACT_11702]) that started on or after the date of the first dose of the study 
drug will be considered a TEAE if it was not present prior to the first dose of study drug, or was 
present prior to the first dose of study drug but increased in intensity during the treatment period. 
If more than [ADDRESS_1267671] dose of study drug that increases in intensity 
during the treat
ment period will be re-entered with a new start date of the date of increased 
intensity. 
Descriptive statistics (the number and percentage) for subjects reporting TEAEs will be tabulated 
by [CONTACT_6657]; by [CONTACT_9313], preferred term, and severity; 
and by [CONTACT_9313], preferred term, and relationship to study drug. If more than [ADDRESS_1267672] related occurrence for the summarization by 
[CONTACT_373436]. 
Listings will be presented for all subjects. Additionally, listings will be presented for subjects 
with SAEs, subjects with AEs leading to discontinuation of study or study drug, and subjects 
who die (if any). 
17.6.5. Vital Signs 
Descriptive statistics for 
vital signs (eg, systolic and diastolic blood pressure, pulse rate, and 
body weight) and their changes from baseline at each visit and at the end of study will be 
presented. Vital signs listings for all subjects will be provided. 
Vital sign values are potentially clinically important (PCI) if they meet both the observed value 
criteria and the change from baseline criteria. The criteria for PCI vital sign values will be 
detailed in the Statistical Analysis Plan (SAP). The PCI percentages will be calculated relative to 
the number of subjects with baseline and at least one post-baseline assessment. A supportive 

EN3835-[ADDRESS_1267673]-baseline values. 
17.6.6. Clinical Laboratory Parameters 
Descriptive statistics for 
clinical laboratory values in International System of Units (SI units) and 
changes from baseline at Day 180 will be presented for each clinical laboratory parameter. 
Listings for clinical laboratory values for all subjects will be provided. 
The number 
and percentage of subjects with potentially clinically important (PCI) post-baseline 
clinical laboratory values will be tabulated. The criteria for PCI laboratory values will be detailed 
in the Statistical Analysis Plan (SAP). The PCI percentages will be calculated relative to the 
number of subjects with at least one post-baseline assessment. A supportive listing of subjects 
with post-baseline PCI values will be provided, including the subject ID, study center, baseline 
and post-baseline values. 
17.6.7. Electrocardiogram 
Not applic
able (ECG is done only at screening for the subject’s enrollment eligibility). 
17.6.8. Physical Exami nation 
Body weight and BMI at Day 22, Day 43, Day 90, and Day 180 as well as their change from 
baseline (Day 1) at those time points will be presented.  
17.6.9. Other Safety Measurements 
Not applica
ble. 
17.7. Pharmacokinetic Analyses 
Not applicable. 
17.8. Pharmacodynamic Analyses 
Not applicable. 
17.9. Other Data (eg, Health Economics/QOL, Pharmacogenetic, etc.) 
Not applicable. 
17.10.  Interim Analysis 
No interim analysis is planned for this study. 
17.11.  Statistical Software 
Statistical analyses will be performed using Version 9.3 (or higher) of SAS® (SAS Institute, 
Cary, NC). 

EN3835-[ADDRESS_1267674] be made available to the clinical monitor, Endo employees, IRB/IEC, 
and regulatory agencies for routine inspection and accountability during monitoring visits. When 
instructed by [CONTACT_260644], the Investigator agrees to return all original used or unused study drug kits to 
Endo's return vendor. 
18.5.1. Study Drug Handli ng and Disposal 
The Investigator agrees not to supply study drug to any person except to those subjects enrolled 
in the study. The Investigator is responsible for recording the receipt and use of all drugs 
supplied and for ensuring the supervision of the storage, allocation, and aseptic preparation of 
these supplies. All used and unused study drug will be returned, and unit counts will be 
performed whenever medication is returned. The site must account for all study drug received 
and its use. At the end of the study, all used and unused drug supplies will be returned to Endo’s 
designated vendor. 

EN3835-[ADDRESS_1267675] ACCESS TO S
OURCE DATA/DOCUMENTS 
19.1. Source Documents 
Source documents include but are not limited to original documents, data and records such as 
hospi[INVESTIGATOR_307]/medical records (including electronic health records), clinic charts, lab results, subject 
diaries, data recorded in automated instruments, microfilm or magnetic media, and pharmacy 
records, etc. At a minimum, all data required to be collected by [CONTACT_260658], unless the protocol specifies that data 
can be recorded directly on/in the eCRF or other device. 
19.2. Study Monitoring 
A representative of Endo Pharmaceuticals Inc. will meet with the Investigator and his/her staff 
prior to the entrance of the first subject to review study procedures and methods of recording 
findings in the eCRF. 
After enrollment of the first subject, an Endo Pharmaceuticals Inc. representative will be 
assigned to periodically monitor each Investigator site for study progress and to verify that 
standards of Good Clinical Practice (GCP) were followed. The Investigator is expected to 
prepare for the monitor visit, ensuring that all source documents, completed eCRFs, signed 
consent forms and other study related documents are readily available for review. 
19.3. Audits and Inspections 
The Investigator shall permit audits and inspections by [CONTACT_1034], its representatives and 
members of regulatory agencies. The Investigator should immediately notify the Sponsor of an 
upcoming FDA
 or other regulatory agency inspection. 
19.4. Institutional Review Board (IRB) 
The Investigator shall permit members of the IRB/IEC to have direct access to source 
documents. 
19.5. Data Recording and Documentation 
All data recordings and source documentation (including electronic health records) must be made 
available to the Sponsor (or designee), FDA and any other regulatory agencies that request 
access to study records, including source documents, for inspection and copying, in keepi[INVESTIGATOR_807562]. 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 58 
   20. QUALITY CONTROL AND 
QUALITY ASSURANCE 
Steps to assure the accuracy and reliability of data include the selection of qualified principal 
investigators and appropriate study centers, review of protocol procedures with the principal 
investigators and associated personnel prior to start of the study, and periodic monitoring visits 
conducted by [CONTACT_46887]. Significant and/or repeated non-compliance 
will be investigated and remedial action instituted when appropriate. Failure to comply with 
remedial actions may result in investigator site termination and regulatory authority notification. 
The Sponsor or its designee will utilize qualified monitors to review and evaluate activities 
conducted at Investigator sites. 
The data will be entered into the clinical study database and verified for accuracy, following 
procedures defined by [CONTACT_1034] (or designee). Data will be processed and analyzed following 
procedures defined by [CONTACT_1034] (or designee). 
The study will be monitored and/or audited at intervals to ensure that the clinical study is 
conducted and data are generated, documented (recorded), and reported in compliance with the 
Study Protocol; International Conference on Harmonisation (ICH), E6 consolidated guidelines; 
and other applicable regulations. The extent, nature, and frequency of monitoring and/or audits 
will be based on such considerations as the study objectives and/or endpoints, the purpose of the 
study, study design complexity, and enrollment rate. At the conclusion of a program, a 
compliance statement will be generated by [CONTACT_1034] (or designee) listing all audit activities 
performed during the clinical study. 
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 59 
   21. ETHICS 
21.1. Ethics Revie
w 
Approval by [CONTACT_1201]/IEC prior to the start of the study will be the responsibility of the 
Investigator. A copy of approval documentation will be supplied to Endo Pharmaceuticals Inc. 
along with a roster of IRB members that demonstrates appropriate composition (a Department of 
Health and Human Services [DHHS] Assurance Number will satisfy this requirement). 
The study protocol, the informed consent form, advertisements, materials being provided to 
subjects and amendments (if any) will be approved to IRB/IECs at each study center in 
conformance with ICH E6, the Code of Federal Regulations (CFR), Title 21, Part 56 and any 
other applicable local laws. The Investigator is responsible for supplying the IRB/IEC with a 
copy of the current IB, Package Insert, or SPC as well as any updates issued during the study. 
During the course of the study, the Investigator will provide timely and accurate reports to the 
IRB/IEC on the progress of the study, at intervals not exceeding 1 year (or as appropriate), and 
will notify the IRB/IEC of SAEs or other significant safety findings, per the policy of the 
IRB/IEC. At the conclusion of
 the study, the Investigator will submit a final report or close out 
report to the IRB/IEC and provide a copy to Endo Pharmaceuticals Inc. 
Any amendment to this protocol will be provided to the Investigator in writing by [CONTACT_596664]. No protocol amendment may be implemented (with the exceptions noted 
below) before it has been approved by [CONTACT_242317], signed by [CONTACT_3786], has been received by [CONTACT_596669]. Where the protocol is amended to 
eliminate or reduce the risk to the subject, the amendment may be implemented before IRB 
review and approval. However, the IRB must be informed in writing of such an amendment and 
approval obtained within reasonable time limits. Deviating from the protocol is permitted only if 
absolutely necessary for the safety or clinical management of the subject, and must be 
immediately reported to Endo Pharmaceuticals Inc. 
The Investigator will be responsible for supplying updated safety and/or study information to 
study subjects as it becomes available. 
21.2. Ethical Conduct of the Study 
This clinical study is designed to comply with the ICH Guidance on General Considerations for 
Clinical Trials (62 FR 6611, December 17, 1997), Nonclinical Safety Studies for the Conduct of 
Human Clinical Trials for Pharmaceuticals (62 FR [ZIP_CODE], November 25, 1997), Good Clinical 
Practice: Consolidated Guidance (62 FR [ZIP_CODE], May 9, 1997) and [ADDRESS_1267676] their questions 
answered sufficiently, will give voluntary and written informed consent (in compliance with ICH 
E6, 4.8, and 21 CFR Parts 50 and 312) before participating in any study-related procedures. The 
consent shall be
 written in a language understandable to the subject. Subjects unable to read 
(illiterate) shall have the consent process performed in the presence of an independent witness 
who shall also sign the consent. Each subject will read, assent understanding, and sign an 
instrument of informed consent after having had an opportunity to discuss the study and consent 
documents with the Investigator before signing, and will be made aware that she may withdraw 
from the study at any time. 
In addition to obtaining informed consent/assent, the Investigator is responsible for obtaining any 
additional documentation to demonstrate compliance with local privacy laws applicable to 
activities performed. 
The consent/assent process shall be recorded in source documents. Signed copi[INVESTIGATOR_742810]/or assent will be given to the Subject/LAR and originals will be placed in the 
Investigator study files.  
A unique Subject identification number will be assigned according to section  [IP_ADDRESS] at the time 
that the
 Subject signs the informed consent form. 
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 61 
   22. DATA HANDLING AND REC
ORDKEEPI[INVESTIGATOR_1645] 
22.1. Data Collection 
Endo will provide an electronic data capture (EDC) system for this study. Data collection will 
involve the use of an EDC system to which only authorized personnel will have access. The 
system will be secured to prevent unauthorized access to the data or the system. This will include 
the requirement for a user ID and password to enter or change data. The level of access to the 
EDC system will be dependent on the person’s role in the study. 
Study data will be collected from source documents and entered into an eCRF within the EDC 
system. The Investigator will be responsible for ensuring the eCRFs are completed in a timely 
manner relative to the subject’s visit. In addition to periodic monitoring occurring within the 
system by a Sponsor monitor, programmatic edit checks will be used to review EDC data for 
completeness, logic, and adherence to the study protocol. As a result of this monitoring and these 
checks, queries may be issued electronically to the clinical study sites and closed electronically 
by [CONTACT_2037], data management staff or authorized staff at the study site. Additionally, the 
Investigator will review eCRFs, ensure all missing or corrected data is provided and will sign the 
eCRF pages with an electronic signature. 
An electronic audit trail will be maintained in the EDC system to track all changes made to data 
entered in the eCRF. Data will be retrievable in such a fashion that all information regarding 
each individual subject is attributable to that subject. Unless otherwise indicated, all data 
captured in the eCRF must first be captured in source documents. Data that can be directly 
recorded in the eCRF will be clearly identified in the section(s) of the protocol that describes the 
assessment(s). 
Data entries will be corrected by [CONTACT_697825]. Any changes or 
corrections to eCRF data will be electronically tracked and will include the reason for correction, 
who made the correction and the date/time stamp when the correction was made within the audit 
trail of the EDC system.  
In addition, any contact [CONTACT_596667]. 
22.2. Study Documentation 
Upon study completion, the Investigator will be provided with complete electronic copi[INVESTIGATOR_596614]/her files. 

EN3835-[ADDRESS_1267677] to mutual agreement between the 
Investigator and Endo Pharmaceuticals Inc. 
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 63 
   24. INVESTIGATOR OBLIGA
TIONS 
24.1. Regulatory Documents 
The Investigator is responsible for creating and/or maintaining all study documentation required 
by 21CFR 50, 54, 56, and 312, ICH, E6 section 8, as well as any other documentation defined in 
the protocol or t
he Investigator Agreement. The Investigator must maintain the documentation 
relating to this study and permit Endo Pharmaceuticals Inc. or a member of a regulatory agency 
access to such records. 
The Investigator must provide the following key documents to Endo Pharmaceuticals Inc. prior 
to the start of the study: 
 A completed and signed Form FDA1572. If during the course of the study any 
informat
ion reported on the Form FDA [ADDRESS_1267678] 
be completed and returned to Endo Pharmaceuticals Inc. for submission to the FDA. 
For studies executed outside the [LOCATION_002], documentation required by [CONTACT_807604] 1572. 
 A fully executed contract 
 The Inve
stigator’s Statement page in this protocol signed and dated by [CONTACT_903772] 
 The IB acknowledgment  of receipt page 
 Curricula vitae for the Principal Investigator [INVESTIGATOR_244293]-Investigators listed on Form 
FDA 1572, i
ncluding a copy of each physician’s license (if applicable) 
 A copy of the ori ginal IRB/IEC approval for conducting the study. If the study is 
ongoing, renewals must be submitted at yearly intervals or shorter intervals defined 
by [CONTACT_1201]/IEC. All subsequent modifications must be submitted and approved by [CONTACT_5040], as described in section 21.1 
 A copy of the IRB/IEC- approved informed consent form 
 A list of IRB/IEC members or DHHS Assurance Number 
 Laboratory certifications and normal ranges (if local labs are required by [CONTACT_760]) 
 A financial disclosure agreement completed and signed by [CONTACT_211435]-Investigators listed on Form FDA 1572. Investigator site staff that submitted an 
initial financial disclosure are also responsible for informing Endo Pharmaceuticals 
Inc. of any changes to their initial financial disclosure form [ADDRESS_1267679] been properly trained on the protocol and their assigned study responsibilities. 
24.3. Medical Care of Study Subjects 
The Investigator and/or a qualified S ub-Investigator shall be responsible for the subjects’ 
medical care. Any unrelated medical condition discovered during the course of the study should 
be communicated to the subject so that they may seek appropriate medical care. The Investigator 
will report all AEs as required by [CONTACT_760] (section 14.5). The Investigator will inform study 
subjects of new information regarding the study drug as it becomes available. 
24.4. Use of Investigational Materials 
The Investigator will acknowledge that the study drug supplies are investigational and as such 
must be used strictly in accordance with the protocol and only under the supervision of the 
Principal Investigator [INVESTIGATOR_54720]-Investigators listed on Form FDA1572 (or other regulatory 
document, d
epending on region). Study drug must be stored in a safe and secure location. At 
study initiation, a representative from Endo Pharmaceuticals Inc. will inventory the study drug at 
the site. The Investigator must maintain adequate records documenting the receipt and 
disposition of all study supplies. Endo Pharmaceuticals Inc. or its representative will supply 
forms to document total inventory as well as subject specific accountability. The Investigator is 
responsible for monitoring subject’s use of the study drug to ensure compliance with the 
protocol. All study supplies shall be returned to Endo Pharmaceuticals Inc. or its designee. 
24.5. Retention of Records 
Federal and local regulations require that the Investigator retain a copy of all regulatory 
documents and r
ecords that support the data for this study (eg, informed consents, laboratory 
reports, source documents, study drug dispensing records) for whichever of the following is the 
longest period of time: 
 A period of [ADDRESS_1267680] of the 
investigation; or 
 A period of [ADDRESS_1267681] be retained for a period of 2 years 
following notification by [CONTACT_596669]. that the entire clinical investigation (not 
merely the Investigator’s portion) is completed, terminated, or discontinued or 2 years following 
withdrawal of the Investigational New Drug application (IND)/Clinical Trial Authorization 
(CTA) or request for marketing approval (New Drug Application [NDA]/Marketing 
Authorization Application [MAA]). 
If the Investigator retires, relocates, or for other reasons withdraws from the responsibility of 
keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept the 
responsibility. Endo Pharmaceuticals Inc. must be notified in writing of the name [CONTACT_19619]. Study records should not be destroyed without consultation with Endo 
Pharmaceuticals Inc. 
24.6. Subject Confidentiality 
All subject records submitted to Endo Pharmaceuticals Inc. or its designee will be identified only 
by [CONTACT_807617]. Subjects’ names are not to be transmitted to Endo 
Pharmaceuticals Inc. The Investigator will keep a Master Subject List on which the identification 
number and the full name, address, and telephone number of each subject are listed. It is the 
Investigators’ responsibility to inform study subjects that representatives of the Sponsor, FDA, or 
other regulatory agencies may review all records that support their participation in the study. The 
Investigator will adhere to all privacy laws to which he/she is subject. 
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 66 
   25. TERMINATION OF STUDY
 
The Sponsor has the right to suspend or terminate the study at any time. The study may be 
suspended or t
erminated for any reason. 
 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 67 
   26. INVESTIGATOR’S STATE
MENT 
I agree to conduct the study in accordance with the protocol, and with all applicable government 
regulations and Good Clinical Practice guidance. 
 
  _____/_____/______ 
Investigator’s Signature [CONTACT_903775]3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 68 
   27. REFERENCES 
1. Khan MH, Victor  F, Rao B, Sadick NS. Treatment of cellulite: Part I. Pathophysiology. 
J Am Acad Dermatol 2010;62(3):36 1-70.  
2. Hexsel D, de Oliveira Dal’Forno T, Mazzuco R. Definition, clinical aspects, 
classifications, and diagnostic techniques. In: Goldman MP, Hexsel D, eds. Cellulite: 
Pathophysiology and Treatment.  2nd ed. [LOCATION_001], NY: Informa Healthcare; 
2010:13-21.
 
3. Rawlings AV. Cellulite and  its treatment. Int J Cosmetic Sci.  2006;28(3):175-90. 
4. Terranova F, Berardesca E, Maibach H. Cellulite: nature and aetiopathogenesis. Int J 
Cosmetic Sc
i. 2006;28(3):157-67. 
5. Avram MM. Cellulite: a review of its physiology and treatment. J Cosmet Laser Ther . 
2004;6(4):181-5. 
6. Khan MH, Victor  F, Rao B, Sadick NS. Treatment of cellulite: Part II. Advances and 
controversies. J Am Acad Dermatol 2010;62(3):373-84. 
7. Collis N, Elliot LA, Sharpe C, Sharpe DT. Cellulite treatment: a myth or reality: a 
prospective 
randomized, controlled trial of two therapi[INVESTIGATOR_014], endermologie and 
aminophylline cream. Plast Reconstr Surg. 1999;104(4):1110-4. 
8. Hexsel DM, Mazzuco R. Subcision: a treatment for cellulite. Int J Dermat ol. 
2000;39(7):539-44. 
9. Boyce S, Pabby A, Chuchal tkaren P, Brazzini B, Goldman MP. Clinical evaluation of a 
device for the treatment of cellulite: Triactive. Am J Cosmet Surg . 2005;22:233-7. 
10. DiBernardo BE. Treatment of celllulite using a 1440-nm pulsed laser with one-year 
follow-
up. Aesthet Surg J.  2011;31(3):328-41. 
11. Investigational Brochure: Collagenase Clostridium Histolyticum for Injection 
(AA4500/EN3835), Ver
sion 7.0. Endo Pharmaceuticals Inc.; May 2016. 
12. Hexsel DM, Dal’Forno T, Hexsel CL. A validated photonumeric cellulite severity scale. 
J Eur Acad Dermatol Vener
eol. 2009;23(5):523-8. 
13. Nürnberger F, Müller G. So-called cellulite: an invented disease. J Dermatol Surg O ncol. 
1978;4(3):221-9. 
 

EN3835-[ADDRESS_1267682] the study and to ensure that the Investigator understands and 
agrees to comply with the protocol, applicable regulations, policies, and procedures. The 
following documentation is required: 
From the Principal Investigator 
1. A signed agreement to perform the study per  protocol (the signature [CONTACT_596696]) 
2. A signed Letter of Financ ial Agreement (including  confidentiality statement) 
3. Name(s) of the Principal Investigator [INVESTIGATOR_596610]-Investigator(s) 
4. All a
ddress(es) of the clinical site(s) 
5. A curr
ent medical license valid where he/she practices and a current curriculum vitae for 
the Pri
ncipal Investigator (signed and dated) and all sub-investigators, to contain at least 
the following elements: 
a. For physicians: 
i. Date of degree in Medicine 
ii. Name [CONTACT_807678]. Previous clinical postings with dates 
b. For non-physician allowed by [CONTACT_903773]: 
i. Date and description of most advanced degree 
ii. Name [CONTACT_596698] (i) 
iii. Other accreditation or qualifications relevant to the study 
iv. Previous postings with dates 
v. Name [CONTACT_596699] (see 5a above) of the physician or dentist in charge of 
study subjects 
Note: If a non
-physician is serving as Principal Investigator, then a qualified physician 
must be assigned as a sub-Investigator for the trial, to be responsible for all trial-related 
medical decisions.  
6. Written notification of Institutional Review Board/Independent Ethics Committee/Human 
Research Et
hics Committee (IRB/IEC/HREC) approval. The minimum requirements are 
as follows: 
a. Dated letter, including: 
i. The date on which the meeting for the review of the study protocol took place 
ii. Study protocol/amendment number, and version date 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 70 
   iii. A clear statement of appr
oval of the protocol and the informed consent text with 
version date, and authorization for the study to pro ceed 
iv. If the Investigator or any Sub-Investigator is a part of the IRB/IEC/HREC 
Review Board, assurance that the I
nvestigator abstained from voting at the 
meeting(s) when the study was discussed 
b. A dated list of the members and their occupations 
c. A specim
en copy of the Committee-approved informed consent text to be used in the 
study 
7. Food and Drug Admini stration (FDA) Form 1572 (for studies submitted under a US 
Investigational New Drug application [IND]) 
8. Financial Disclosure Certification or Certification of Non-Disclosure (for studies to be 
submit
ted for a US New Drug Application/Biologics License Application [NDA/BLA]) 
Other 
Any other documentation required by [CONTACT_903774]. 

EN3835 -205 Protocol  
31-Aug-2017  Endo Pharmaceuticals Inc. Page 71  
   APPENDIX B. CLINICIAN-REPORTED PHOTONUMERIC CELLULITE SEVERITY SCALE 
(CR-PCSS) FOR THE BUTTOCK 
 

EN3835 -205 Protocol  
31-Aug-2017  Endo Pharmaceuticals Inc. Page 72  
   APPENDIX C. CLINICIAN-REPORTED PHOTONUMERIC CELLULITE SEVERITY SCALE 
(CR-PCSS) FOR THE THIGH 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 73 
   APPENDIX D. HEXSEL DM, DAL’
FORNO T, HEXSEL CL. A 
VALIDATED PHOTONUMERIC CELLULITE SEVERIT Y 
SCALE. J EUR ACAD DERMATOL VENEREOL . 
2009;23(5):523-8 

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 74 
    

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 76 
     

EN3835-205 Protocol  
31-Aug-2017 Endo Pharmaceuticals Inc. Page 79 
    
